Use of the IL-6R Antagonist Tocilizumab in Hospitalized COVID-19 Patients.

Publication Title

Journal of internal medicine

Authors

• Krish Patel, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USAFollow
• Ted A Gooley
• Neil Bailey, Swedish Cancer Center, Seattle, WAFollow
• Megumi Bailey, Swedish Medical Center, Seattle, Washington, United States.Follow
• Livia Hegerova, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, Washington.Follow
• Ami Batchelder, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Follow
• Heather Holdread, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Follow
• Vanessa Dunleavy, Swedish Medical Center, Seattle, Washington, United States.Follow
• Tyler Downey, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Follow
• Jens Frisvold, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Follow
• Samantha Megrath, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Follow
• Krystle Pagarigan, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Follow
• Jennie Szeto, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Follow
• Justin Rueda, Divisions of Infectious Disease, Swedish Medical Center, Seattle, WA, USA.Follow
• Adel Islam, Divisions of Infectious Disease, Swedish Medical Center, Seattle, WA, USA.Follow
• Cynthia L Maree, Swedish Medical GroupFollow
• Sonam Nyatsatsang, Divisions of Infectious Disease, Swedish Medical Center, Seattle, WA, USA.Follow
• Sarah E Bork, Hospital Medicine, Swedish Medical Center, Seattle, WA, USA.Follow
• Anne B Lipke, Swedish Medical CenterFollow
• D Shane O'Mahony, Pulmonary and Critical Care, Swedish Medical Center, Seattle, WA, USA.Follow
• Teresa E Wagner, Swedish Medical CenterFollow
• Juan Pulido
• John Mignone
• Samuel Youssef
• Matthew Hartman
• Jason D Goldman, Division of Infectious Diseases Swedish Medical Center Seattle WA.Follow
• John M Pagel, Swedish Cancer InstituteFollow

Document Type

Article

Publication Date

8-3-2020

Keywords

2019-nCoV

Abstract

Severely ill COVID-19 patients have a high risk of admission to the intensive-care unit (ICU) and requirement for mechanical ventilation (MV), with in-hospital mortality reported as 18-79% globally.1-4 . Among ICU patients in the United States (US), centers have reported 50% mortality.5,6 Tocilizumab, an IL-6 receptor (IL-6R) antagonist, is FDA approved for the management of CAR T-cell related Cytokine Release Syndrome (CRS) and may have utility in treatment of some COVID-19 patients. We describe the clinical characteristics and initial outcomes of a cohort of patients treated with tocilizumab at the Swedish Medical Center in Seattle, Washington.

Area of Special Interest

Cancer

Specialty/Research Institute

Infectious Diseases

Specialty/Research Institute

Internal Medicine